These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29543757)

  • 1. ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.
    Vrana D; Hlavac V; Brynychova V; Vaclavikova R; Neoral C; Vrba J; Aujesky R; Matzenauer M; Melichar B; Soucek P
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29543757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer.
    Rumiato E; Boldrin E; Amadori A; Saggioro D
    Pharmacogenomics; 2016 May; 17(7):805-20. PubMed ID: 27181132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
    Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Park S; Shimizu C; Shimoyama T; Takeda M; Ando M; Kohno T; Katsumata N; Kang YK; Nishio K; Fujiwara Y
    Breast Cancer Res Treat; 2006 Sep; 99(1):9-17. PubMed ID: 16752223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review.
    Li Y; Liu J; Cai XW; Li HX; Cheng Y; Dong XH; Yu W; Fu XL
    Crit Rev Oncol Hematol; 2021 Nov; 167():103466. PubMed ID: 34508841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
    von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
    Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer.
    Li J; Ma S
    Thorac Cancer; 2021 Sep; 12(17):2293-2299. PubMed ID: 34254738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Predictive Role of MicroRNAs in the Neoadjuvant Treatment of Esophageal Cancer.
    Vrana D; Matzenauer M; Aujesky R; Vrba R; Neoral C; Melichar B; Souček P
    Anticancer Res; 2017 Feb; 37(2):403-412. PubMed ID: 28179285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
    Fu JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
    Honing J; Pavlov KV; Mul VE; Karrenbeld A; Meijer C; Faiz Z; Smit JK; Hospers GA; Burgerhof JG; Kruyt FA; Kleibeuker JH; Plukker JT
    Radiother Oncol; 2015 Oct; 117(1):152-8. PubMed ID: 26364884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
    Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
    J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.
    Piro G; Carbone C; Santoro R; Tortora G; Melisi D
    Expert Rev Mol Diagn; 2018 Apr; 18(4):357-370. PubMed ID: 29544370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
    Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
    Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.